ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

Published Date: 24 Jun 2024

Phase II study found brigatinib exceeded historical control by shrinking 10% of targeted tumors

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Telemedicine services linked to reducing excess mortality

2.

Primary Sjögren's syndrome patients' B-Cell Stimulating Factors are associated with the growth of lymphomas.

3.

Aster Whitefield Hospital, with 506 beds, opened.

4.

Treatment of Smoldering Myeloma Cuts Progression Rate in Half

5.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot